We report the findings of a questionnaire distributed by the Committee of Supportive Care of the Japan Adult Leukemia Study Group to 196 hospitals throughout Japan. For antimicrobial prophylaxis, the oral quinolones are prescribed by 38% of physicians and polymixin B by 31%. For antifungal prophylaxis, amphotericin B is prescribed by 42% of physicians and fluconazole by 41%. Febrile neutropenia is empirically treated with cephalosporin or carbapenem monotherapy by 35% of physicians. Overall, dual therapy (i.e., an aminoglycoside plus a cephalosporin, a carbapenem, or an antipseudomonal penicillin) is prescribed by 50% of physicians. When response to initial empirical therapy does not occur after 3-4 days, 51% of physicians add an antifungal agent; fluconazole is preferred to amphotericin B (prescribed by 66% vs. 28% of physicians). For the treatment of fungemia due to Candida albicans, fluconazole was prescribed by 59% of physicians in cases of stable disease and amphotericin B was prescribed by 57% of physicians in cases of unstable disease. Amphotericin B is selected to treat invasive aspergillosis, but a dose of 0.5-0.7 mg/kg, inadequate for this disease, is prescribed by 44% of physicians. Granulocyte colony-stimulating factor is prescribed to treat patients with acute myelogenous leukemia who have life-threatening infections (27% of physicians) or who have clinically or microbiologically documented infections (26% of physicians).
The Japan Adult Leukemia Study Group (JALSG) is a nationwide group concerned with treatment of leukemia. The JALSG Committee of Supportive Care developed a fact-finding questionnaire regarding the management of infectious complications associated with acute myelogenous leukemia for distribution to the steering committees of 196 hospitals throughout Japan. The findings of this survey show the trend of current clinical practice for the management of febrile neutropenia and will provide support for the development of guidelines in Japan. The JALSG also performed an analysis of the infectious complications that occurred in 577 patients undergoing remission induction therapy [1] . The analysis revealed the incidence of microbiologically documented infection was 21%, the incidence of clinically documented infection was 32%, and the incidence of unexplained fever was 41%. Of the 68 cases of bacteremia or fungemia, 41% were due to gramnegative bacteria, 40% to gram-positive bacteria, and 16% to fungi; 3% were polymicrobial cases.
METHODS
The survey prepared by the Committee of Supportive Care of the JALSG was mailed in July 2001 to the steering committees responsible for the treatment of leukemia at each of the 196 hospitals. The survey was designed to assess the current practice patterns with respect to prophylaxis, empirical therapy, modification of initial therapy, antifungal therapy, and granulocyte colony-stimulating factor (G-CSF) treatment during remission induction chemotherapy for acute myelogenous leukemia. Change from first-line empirical antibiotics to second-line antibiotics and add antifungal(s) 34
Continue with first-line empirical antibiotics and add vancomycin and antifungal(s) 3
Change from first-line empirical antibiotics to second-line antibiotics and add vancomycin and antifungal(s) 2
Other 5
RESULTS
Of the 196 steering committees, 125 (64%) answered the survey.
The physicians who took part in this study were active members responsible for the care of patients with leukemia at each of the hospitals. Prophylaxis. For antibacterial prophylaxis, the oral quinolones were prescribed by 38% of physicians, polymixin B by 31%, trimethoprim-sulfamethoxazole by 16%, and other agents by 10%; no prophylaxis was prescribed by 6% of physicians. For antifungal prophylaxis, oral amphotericin B was prescribed by 42% of physicians, fluconazole by 41%, itraconazole capsules by 10%, and other agents by 4%; no prophylaxis was prescribed by 3% of physicians. More than 90% of physicians prescribed prophylaxis during remission induction therapy for acute myelogenous leukemia.
Empirical antibiotic therapy.
For empirical antibiotic treatment of febrile neutropenia, cephalosporin or carbapenem monotherapy was prescribed by 35% of physicians (table 1) . The frequency of administration of drugs as single agents is as follows: cefepime, 27%; ceftazidime, 17%; cefpirome, 5%; cefozopran, 6%; cefoperazone/sulbactam, 2%; imipenem/cilastatin, 6%; panipenem/betamipron, 21%; meropenem, 9%; and other, 6%. Two-drug therapy with an aminoglycoside plus a cephalosporin, a carbapenem, or an antipseudomonal penicillin was prescribed by 50% of physicians. A cephalosporin plus aminoglycoside regimen was the most commonly prescribed (29%). Vancomycin was prescribed as part of the initial empirical therapy by only 1% of physicians. This is mainly because the National Health Insurance of Japan allows the use of vancomycin only in cases with documented methicillin-resistant Staphylococcus aureus infection. Table 2 shows the second-line antimicrobials and antifungals prescribed to patients who did not respond 72-96 h after the start of the initial empirical therapy. Forty-four percent of physicians modified treatment regimens to include second-line antibiotics and added an antifungal agent to regimens after another 48-72 h. Fifty-one percent of physicians added an antifungal agent for patients with infection refractory to the initial empirical therapy after 72-96 h. With initial monotherapy, 61% of physicians preferred to change to a second-line antibiotic therapy, and 37% added an antifungal agent to regimens after 72-96 h. These 2 types of regimen changes were made by 42% and 53% of physicians, respectively, if 2-drug therapy was initially given (data not shown).
Empirical and targeted antifungal therapy. For empirical antifungal treatment, fluconazole was preferred over amphotericin B (prescribed by 66% and 28% of physicians, respectively) (table 3). For the treatment of fungemia due to Candida albicans, fluconazole was prescribed by 59% of physicians in cases of stable disease and amphotericin B was prescribed by 57% of physicians in cases of unstable disease (defined as the presence of unstable vital signs plus pneumonia or hepatosplenic candidiasis). To treat invasive pulmonary aspergillosis, the preferred choice was amphotericin B, but 44% of patients received it at a dose of 0.5-0.7 mg/kg, which is not adequate for this disease.
Use of G-CSF. G-CSF was most often used to treat cases of life-threatening infection (prescribed by 27% of physicians), followed by cases of clinically or microbiologically documented infection (26% of physicians) in patients with acute myelogenous leukemia undergoing remission induction therapy (table 4). On the other hand, among patients with acute lymphocytic leukemia, prophylactic use of G-CSF was most common (52% of physicians), followed by use to treat febrile neutropenia (20% of physicians). A similar trend was observed for patients undergoing consolidation therapy for acute leukemia.
DISCUSSION
In 1990, the Infectious Diseases Society of America published evidence-based guidelines for the management of febrile neutropenia, with revisions in 1997 and in 2002 [2] [3] [4] . Although these guidelines are useful in Japan, there are several differences in the health care systems of the United States and Japan. For example, the National Health Insurance in Japan covers all medical costs above ∼US$500/month or $1000/month for patients with an annual income of 1$50,000. Therefore, all induction and consolidation therapies are administered to inpatients, and oral antibiotics are seldom prescribed for empirical therapy for febrile neutropenia, even for patients at low-risk. The licensed antibiotics are different, and the approved dosages are also lower in Japan (e.g., the maximum daily dose of ceftazidime is 4 g, that of imipenem is 2 g, and that of piperacillin/tazobactam is 5 g). The National Health Insurance of Japan supports the use of vancomycin or teicoplanin only for patients with documented methicillin-resistant Staphylococcus aureus infection. Thus, it is difficult to use vancomycin as part of initial empirical therapy. Approved intravenous antifungal agents also differ; at present, they are amphotericin B, fluconazole, miconazole, and the recently approved micafungin. Another difference in the diagnostic approach is the wide use of serological testing for identification of fungal infections [5] . More than 90% of physicians measure plasma b-D-glucan for the screening of systemic fungal infections. Approximately 40% of physicians measure serum galactomannan to screen for suspected aspergillosis, and only 14% use PCR for the diagnosis of invasive aspergillosis or other fungal infections (data not shown).
The criteria for starting G-CSF therapy also differ in the United States and Japan [6] . In Japan, G-CSF is administered to patients with solid tumors or lymphoid malignancies if their neutrophil counts are !1000 cells/mm 3 . Empirical G-CSF therapy is permitted for patients with acute leukemia after chemotherapy, regardless of the neutrophil count. However, most Japanese physicians prefer to use G-CSF for documented or life-threatening infections in patients with acute myelogenous leukemia, because of the possible stimulating activity of G-CSF on acute myelogenous leukemia cells. This is quite different from treatment of patients with acute lymphocytic leukemia, for whom most physicians use G-CSF during neutropenia.
In conclusion, there were several differences in clinical practices for the management of febrile neutropenia between the United States and Japan. The data collected from the survey may aid in the development of the Japanese guidelines for the management of febrile neutropenia.
